Nucleoside reverse transcriptase inhibitors with reduced predicted activity do not impair second-line therapy with lopinavir/ritonavir or darunavir/ritonavir - fdi:010072771 - Horizon

Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

Publications des scientifiques de l'IRD

Villabona-Arenas C. J., Eymard-Duvernay Sabrina, Aghokeng Fobang Avelin, Guichet E., Toure-Kane C., Bado G., Koulla-Shiro S., Delaporte E., Ciaffi L., Peeters Martine. (2018). Nucleoside reverse transcriptase inhibitors with reduced predicted activity do not impair second-line therapy with lopinavir/ritonavir or darunavir/ritonavir. Aids Research and Human Retroviruses, Ehead of print, 4 p. ISSN 0889-2229

Accès réservé (Intranet IRD) Document en accès réservé (Intranet IRD)

Lien direct chez l'éditeur doi:10.1089/aid.2017.0290

Titre
Nucleoside reverse transcriptase inhibitors with reduced predicted activity do not impair second-line therapy with lopinavir/ritonavir or darunavir/ritonavir
Année de publication2018
Type de documentArticle référencé dans le Web of Science WOS:000430599400001
AuteursVillabona-Arenas C. J., Eymard-Duvernay Sabrina, Aghokeng Fobang Avelin, Guichet E., Toure-Kane C., Bado G., Koulla-Shiro S., Delaporte E., Ciaffi L., Peeters Martine.
SourceAids Research and Human Retroviruses, 2018, Ehead of print, 4 p. ISSN 0889-2229
RésuméSecond-line therapy randomized trials with lopinavir/ritonavir question the value of resistance testing to guide nucleoside reverse transcriptase inhibitor (NRTI) selection. In this study, we investigated the association between baseline drug resistance and treatment outcome after 104 weeks of second-line therapy with NRTIs and either darunavir/ritonavir or lopinavir/ritonavir in West-central Africa. We did an observational analysis of data from 387 individuals in a randomized, open-label 2LADY trial in Burkina Faso, Cameroon, and Senegal. We modeled the association between RTI drug resistance mutations (DRMs) and virological failure (VF) (viral load [VL] <50 copies/mL) at week 104 using logistic regressions. Covariates included baseline VL and CD4(+) count, demographic, and adherence data. Overall, 193 (49.9%), 150 (38.8%), and 44 (11.4%) individuals had, respectively, low/none (genotypic susceptibility score [GSS] <1), intermediate (GSS=1), and high predicted NRTI activity (GSS >1) in their prescribed second-line regimen. The average number of DRMs by drug class, the proportion of individuals by GSS category, and the duration of first-line therapy were not associated with VF (p>.05). High VL at switch was the only consistent prognostic factor for VF after multivariate adjustment (p<.01). Suboptimal adherence, high predicted RTI activity, or low NRTI mutations were associated with VF (p<.05) when using higher end points for VF or in the intention-to-treat analysis. In conclusion, the use of RTIs with predicted reduced activity does not impair second-line protease inhibitor-based therapy. Therefore, HIV care in resource-limited settings should prioritize strategies to improve adherence and targeted VL testing over drug resistance testing for selecting NRTIs during a protease-based second-line switch.
Plan de classementSanté : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Descr. géo.BURKINA FASO ; SENEGAL ; CAMEROUN
LocalisationFonds IRD [F B010072771]
Identifiant IRDfdi:010072771
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010072771

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Nouméa

Papeete

Niamey

Ouagadougou

Tunis

La Paz

Quito